1st World NET Forum
A Forum on Basic and Translational Science in Neuroendocrine Neoplasms

Hybrid Event
8 – 9 March 2022 | Barcelona | Spain

PROGRAMME

ENETS
1st World NET Forum – A Forum on Basic and Translational Science in Neuroendocrine Neoplasms

Programme
8 - 9 March 2022 - Hybrid Event

Tuesday, 08 March 2022

Welcome
Time: Tuesday 11:00 - 11:10
Marianne Fevel, GER

Session 1: Models in NET research
Time: Tuesday 11:10 - 12:20
Chairs: Jia Chen, CHN / Anna Couvelard, FRA / Simon Singh, CAN

11:10 - 11:40 Keynote address: An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping
Kenta Kawasaki, JPN

11:40 - 12:00 Talk 1: State-of-the-art NET tumor models: Present & future
Dawn Quelle, USA

12:00 - 12:20 Discussion

Coffee break
Time: Tuesday 12:20 - 12:30

Session 2: NET tumor biology advances
Time: Tuesday 12:50 - 14:45
Chairs: Emily Berzinsland, USA / Aurel Perren, SUI

12:50 - 13:20 Keynote address: Understanding tumor biology of NEN by integrated genomic analysis
Alba Scipio, ITA

13:20 - 13:30 Discussion

13:30 - 13:45 Talk 1: Epigenetic control of human intestinal neuroendocrine cell differentiation
Ramesh Shikhmasani, USA

13:45 - 13:55 Discussion

13:55 - 14:10 Talk 2: Immune and stromal heterogeneity associated with cellular origin and cancer evolution in GEP-NET
Anguree Sadanandam, GBR

14:10 - 14:20 Discussion

14:20 - 14:35 Talk 3: Mechanisms of RB loss in neuroendocrine carcinoma
Nancy Joseph, USA

14:35 - 14:45 Discussion

Summary of sessions 1 & 2
Time: Tuesday 14:45 - 15:00
Justo P. Castaño, ESP

Coffee break
Time: Tuesday 15:00 - 15:30
# Oral abstract presentations - Part I

**Time:** Tuesday 15:30 - 16:55  
**Chairs:** Hiromitsu Sasano, JPN / Ramesh Shvidansari, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30</td>
<td>Characterising aggressive pulmonary carcinoids through integrative omics analysis</td>
<td>Alexandre Sexton-Gates, FRA</td>
</tr>
<tr>
<td>15:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td>Broncho-pulmonary combined large-cell neuroendocrine carcinomas (Co-LCNEC): More than a hybrid neoplasm</td>
<td>Michele Simba, ITA</td>
</tr>
<tr>
<td>16:00</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:10</td>
<td>Molecular, histopathological, and functional characterization of the dysregulation of the splicing machinery in lung carcinoids</td>
<td>Victor Garcia-Vozque, ESP</td>
</tr>
<tr>
<td>16:20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Comprehensive transcriptomic and methylomic analysis of NENs from multiple origins show subgroups of patients with clinical relevance</td>
<td>Carlos Carreteiro, ESP</td>
</tr>
<tr>
<td>16:40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>16:50</td>
<td>Summary - Part I</td>
<td></td>
</tr>
</tbody>
</table>

## Coffee break

**Time:** Tuesday 16:55 - 17:15

# Oral abstract presentations - Part II

**Time:** Tuesday 17:15 - 19:00  
**Chairs:** Douglas Hanahan, SU / Eva Tensu Janson, SWE

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>Molecular deciphering of primary liver neuroendocrine neoplasms confirms its distinct existence with foregut-like profile</td>
<td>Louis de Mester, FRA</td>
</tr>
<tr>
<td>17:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:35</td>
<td>Epigenetic aging and metabolic traits of multi-focal ileal neuroendocrine tumors</td>
<td>Amy Webster, UBR</td>
</tr>
<tr>
<td>17:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>17:55</td>
<td>Tumor neoangiogens shape the immune microenvironment of PanNETs: An in silico analysis</td>
<td>Mauro Cives, ITA</td>
</tr>
<tr>
<td>18:05</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:15</td>
<td>Epigenetic progression steps in alpha-lineage MEN1-DAXX/ATRX mutated Pancreatic Neuroendocrine Tumors (PanNET)</td>
<td>Ilaria Marini, SUI</td>
</tr>
<tr>
<td>18:25</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:35</td>
<td>Novel patient-derived tumor organoid models reveal growth-factor dependencies in neuroendocrine tumors and serve as a platform for neuroendocrine cancer research</td>
<td>Taliya Dayton, NED</td>
</tr>
<tr>
<td>18:45</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>18:55</td>
<td>Summary - Part II</td>
<td></td>
</tr>
</tbody>
</table>

19:00 |
Welcome
Time: Wednesday 11:00 - 11:10

Session 3: Therapeutic advances in NET
Time: Wednesday 11:10 - 12:40
Chairs: Bertram Wiedenmann, GER / Hong Zhao, CHN

11:10 - 11:40 Keynote address: Deciphering NET tumor invasiveness to potentiate real therapy candidates
   Douglas Hanahan, SUI
11:40 - 11:50 Discussion
11:50 - 12:05 Talk 1: From genomics to functional genomics: The discovery and targeting of ATRX and MEN1 mutations in PanNETs
   Yuchen Jiao, CHN
12:05 - 12:15 Discussion
12:15 - 12:30 Talk 2: Mechanisms of resistance to PPRT and overcoming these
   Rod Hicks, AUS
12:30 - 12:40 Discussion

Coffee break
Time: Wednesday 12:40 - 13:10

Session 4: Novel areas in NET diagnostic and therapy
Time: Wednesday 13:10 - 14:40
Chairs: B.A. Krishna, IND / Kjell Öberg, SWE / Hitonobu Sasama, JPN

11:10 - 12:40 Keynote address: Precision oncological approach in neuroendocrine tumors (lessons from NET and other cancers)
   Andrea Calitano, USA
13:40 - 13:50 Discussion
13:50 - 14:05 Talk 1: New radionuclides for improved diagnosis and therapy in NET
   Cratina Müller, SUI
14:05 - 14:15 Discussion
14:15 - 14:30 Talk 2: CAR-T cell technology
   Xiaolin Hua, USA
14:30 - 14:40 Discussion

Summary of the day
Time: Wednesday 14:40 - 14:55
Marianne Pavel, GER

Closing comments
Time: Wednesday 14:55 - 15:05
Marianne Pavel, GER